Keith S. Kaye – författare

Dr. Kaye and Dr. Dhor have assembled top experts to write about facility planning and management in Part I of their two issues devoted to Infection Prevention and Control in Healthcare. Articles in this issue are devoted to: Building a Successful Infection Control Program: Key Components, Processes and Economics; Hand Hygiene Sterilization; High Level Disinfection and Environmental Cleaning; Environement of Care; Infection Control in Alternative Healthcare Settings (Long Term Care and Ambulatory); Antibiotic Stewardship; Outbreak InvestigationsWater Safety in Healthcare/Legionella in the Healthcare Setting; Construction and Renovation; Bloodborne and Body Fluid Exposures - prevention and management of Occupational Health Issues; and Informatics and Statistics in Infection Control. Part II is devoted to clinical management of infections.

Dr. Kaye and Dr. Dhor have assembled top experts to write about clinical management of infections in Part II of their two issues devoted to Infection Prevention and Control in Healthcare. Articles in this issue are devoted to: CLABSI; UTI; Tuberculosis; Ventilator-Assisted Pneumonia; Surgical Site Infection; MRSA; VRE; Gram-Negative Bacilli; Fungal Infections; C. Difficile, and Emerging Infections including Ebola. Infectious Disease physicians and anyone in the hospital setting will find this issue very useful, as state-of-the-art clinical reviews provide clinical management on these common and emerging infections.

Infection Prevention and Control in Healthcare, Part II: Clinical Management of Infections, An Issue of Infectious Disea

Infection Prevention and Control in Healthcare, Part I: Facility Planning, An Issue of Infectious Disease Clinics of Nor

In this issue of Infectious Disease Clinics of North America, guest editors Drs. Keith S. Kaye and Sorabh Dhar bring their considerable expertise to the topic of Infection Prevention and Control in Healthcare, Part 1. In the next five years, it is anticipated that healthcare facilities will continue to evolve by integrating advanced technologies and infrastructure improvements to strengthen IPC programs, adopting innovative solutions to monitor and control infections. In this Part One issue, top experts provide state-of-the-art information to infectious disease clinicians on these innovations in preventing healthcare-associated infections.

In this issue of Infectious Disease Clinics of North America, guest editors Drs. Keith S. Kaye and Sorabh Dhar bring their considerable expertise to the topic of Infection Prevention and Control in Healthcare, Part 2. In the next five years, it is anticipated that healthcare facilities will continue to evolve by integrating advanced technologies and infrastructure improvements to strengthen IPC programs, adopting innovative solutions to monitor and control infections. In this Part Two issue, top experts provide state-of-the-art information to infectious disease clinicians on these innovations in preventing healthcare-associated infections.

Infectious diseases is a rapidly changing field in which new organisms emerge, previously identified organisms develop resistance to treatment, and infections that had previously almost disappeared become resurgent. These factors require rapid changes in therapeutic approaches, especially in the use of antimicrobial agents. This issue covers antibiotics in specific populations (children, the elderly, and patients with renal failure), antimicrobial resistance, and new drugs in several classes, including macrolides, fluoroquinolones, beta-lactam antibiotics, and agents for gram-positive infections.

This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy.� New drugs are covered, as well as new approaches.� Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.

This volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field.It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research.This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative ‘superbugs’.

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives.

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives.

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives.